Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

Table 2

Objective responses of liver cirrhosis patients with advanced HCC treated after 4–8 weeks of sorafenib treatment.

Dose of sorafenib	PR	SO	PO	Response rate (%)
200 m g (n = 11); (1 dropout)	0	2	8	0.0
400 mg (n = 27); (3 dropout)	4	11	9	16.7
800 mg (n = 7); (0 dropout)	1	3	3	14.3